HIVプロテアーゼ
シグナル伝達経路
研究分野
阻害剤の選択性比較
| カタログ番号 | 製品カタログ | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | アルコール | ||
| S1185 | Ritonavir | <1 mg/mL | 100 mg/mL | 3 mg/mL |
| S1380 | Lopinavir | <1 mg/mL | 126 mg/mL | 126 mg/mL |
| S1457 | Atazanavir Sulfate | <1 mg/mL | 104 mg/mL | <1 mg/mL |
| S1620 | Darunavir Ethanolate | <1 mg/mL | 100 mg/mL | <1 mg/mL |
| S1639 | Amprenavir | <1 mg/mL | 16 mg/mL | 100 mg/mL |
| S6625 | Temsavir (BMS-626529) | <1 mg/mL | 95 mg/mL | <1 mg/mL |
| S6581 | Fosamprenavir calcium salt | <1 mg/mL | 100 mg/mL | 3 mg/mL |
| S5250 | Darunavir | <1 mg/mL | 100 mg/mL | 11 mg/mL |
| s9010 | Bevirimat | -1 mg/mL | 100 mg/mL | -1 mg/mL |
| S2319 | Limonin | <1 mg/mL | 44 mg/mL | <1 mg/mL |
| S4662 | Atazanavir | <1 mg/mL | 71 mg/mL | 32 mg/mL |
| S9567 | Indinavir Sulfate | -1 mg/mL | 100 mg/mL | -1 mg/mL |
| S4282 | Nelfinavir Mesylate | <1 mg/mL | 100 mg/mL | 100 mg/mL |
| S7381 | Pepstatin A | <1 mg/mL | 57 mg/mL | 1 mg/mL |
| S5245 | Raltegravir potassium | <1 mg/mL | 96 mg/mL | 10 mg/mL |
HIV Protease製品
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| S1185 |
RitonavirRitonavir is a Cytochrome P450 3A and Protease Inhibitor; Also inhibits Cytochrome P450 2D6, P-Glycoprotein and induces Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6 and UDP Glucuronosyltransferases. |
(A) KMS11 and
(B) L363 cells were plated in 5mM glucose medium with ritonavir or DMSO (D) for 17 hours. Glucose consumption rates are normalized to untreated cells (not shown).
(C) KMS11 and (D) L363 cells were treated with ritonavir or DMSO for 72 hours. Relative viable cell numbers were determined by MTS assay and normalized to
untreated cells (not shown).
|
|
| S1380 |
LopinavirLopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM in a cell-free assay. |
Low-micromolar amounts of chloroquine, chlorpromazine, loperamide, and lopinavir inhibit MERS-CoV-induced cytopathology. Huh7 cells in 96-well plates were infected with MERS-CoV isolate EMC/2012 (MOI, 0.005) in the presence of 0 to 20 uM LPV. Cells were incubated for 2 days, and cell viability was monitored using an MTS assay. In addition, the potential toxicity of compound treatment only was monitored in parallel mock-infected Huh7 cell cultures. Graphs show the results (averages and standard deviations [SD]) of a representative experiment that was performed in quadruplicate. All experiments were repeated at least twice. For each compound, the calculated EC50, CC50, and SI values are given.
|
|
| S1457 |
Atazanavir SulfateAtazanavir Sulfate is a HIV protease inhibitor with Ki of 2.66 nM in a cell-free assay. |
Protease inhibitors induce macroautophagy. JEG3 were seeded on glass chamber slides (1 x 104 cell per chamber; 8-well μ slides; Ibidi, Martinsried, Germany), grown for 24 h under cell culture conditions, and treated for 24 h with 0-10 ug/ml of either lopinavir/ritonavir or atazanavir. Cells were then incubated for 30 min with the blue-green fluorescent autophagy marker monodansylcadaverine and viewed under a fluorescence microscope.
|
|
| S1620 |
Darunavir EthanolateDarunavir Ethanolate (DRV) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection. |
HIV PIs variably alter intracellular HIV epitope stability. (A) HLA-A02–restricted SL9 epitope (SLYNTVATL, aa 77–85 in HIV-1 Gag p17) was degraded in PBMC extracts pretreated with DMSO (control, circles), 5 µM of Nelfinavir (triangles) or 5 µM of Saquinavir (squares). Remaining peptide was quantified by RP-HPLC analysis after 0, 10, 30 and 60 minutes. 100% represents the amount of peptide at time 0 calculated as the surface under the peptide peak detected by RP-HPLC (815.986, 821.569, and 813.118 for DMSO, Saquinavir, and Nelfinavir, respectively). Times at which 50% of the SL9 peptide remained correspond to peptide half-lives (37 min, 52 min and 24 min for Control, Saquinavir and Nelfinavir respectively). (B–F) HLA-A02–SL9, HLA-B57-KF11, HLAB57-ISW9, HLA-B57-TW10 and HLA-A11-ATK9 epitopes (from B to F respectively) were degraded in PBMC extracts pretreated with DMSO, 2 µM or 5 µM PI (Saquinavir, Ritonavir, Nelfinavir, Atazanavir or Darunavir). The cytosolic half-lives in control condition were 33.87, 25.66, 14.83, 119.4 and 37.21 minutes for SL9, KF11, ISW9, TW10 and ATK9 respectively. Fold differences of each epitope half-life upon treatment compared to control are presented in each panel. All data represent the average of 4 different experiments using 4 different PBMC extracts. *P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA with Dunnett’s post-test. |
|
| S1639 |
AmprenavirAmprenavir is a potent PXR-selective agonist, and an HIV protease inhibitor, used to treat HIV. |
||
| S6625新 |
Temsavir (BMS-626529)Temsavir (BMS-626529) is a novel small-molecule HIV-1 attachment inhibitor active against both CCR5- and CXCR4-tropic viruses. |
||
| S6581新 |
Fosamprenavir calcium saltFosamprenavir is a pro-drug of the protease inhibitor and antiretroviral drug amprenavir. It is used for the treatment of HIV-1 infections. |
||
| S5250 |
DarunavirDarunavir is a nonpeptidic HIV protease inhibitor, used to treat HIV infection. |
||
| s9010 |
BevirimatBevirimat, the prototype Human Immunodeficiency Virus type 1 (HIV-1) maturation inhibitor, is highly potent in cell culture and efficacious in HIV-1 infected patients. |
||
| S2319 |
LimoninLimonin is a triterpenoid enriched in citrus fruits, which has antivirus and antitumor ability. |
||
| S4662 |
AtazanavirAtazanavir is an azapeptide and HIV-protease inhibitor that is used in the treatment of HIV infections and AIDS in combination with other anti-HIV agents. |
||
| S9567 |
Indinavir SulfateIndinavir sulfate is a specific and potent inhibitor of HIV-1 protease and is widely used in the treatment of AIDS. |
||
| S4282 |
Nelfinavir MesylateNelfinavir Mesylate is a potent HIV protease inhibitor with Ki of 2 nM. |
||
| S7381 |
Pepstatin APepstatin A is a potent aspartic protease inhibitor, and also inhibits HIV replication. |
||
| S5245 |
Raltegravir potassiumRaltegravir Potassium is the orally bioavailable potassium salt of raltegravir, the first approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor. |
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| S1185 |
RitonavirRitonavir is a Cytochrome P450 3A and Protease Inhibitor; Also inhibits Cytochrome P450 2D6, P-Glycoprotein and induces Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6 and UDP Glucuronosyltransferases. |
(A) KMS11 and
(B) L363 cells were plated in 5mM glucose medium with ritonavir or DMSO (D) for 17 hours. Glucose consumption rates are normalized to untreated cells (not shown).
(C) KMS11 and (D) L363 cells were treated with ritonavir or DMSO for 72 hours. Relative viable cell numbers were determined by MTS assay and normalized to
untreated cells (not shown).
|
|
| S1380 |
LopinavirLopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM in a cell-free assay. |
Low-micromolar amounts of chloroquine, chlorpromazine, loperamide, and lopinavir inhibit MERS-CoV-induced cytopathology. Huh7 cells in 96-well plates were infected with MERS-CoV isolate EMC/2012 (MOI, 0.005) in the presence of 0 to 20 uM LPV. Cells were incubated for 2 days, and cell viability was monitored using an MTS assay. In addition, the potential toxicity of compound treatment only was monitored in parallel mock-infected Huh7 cell cultures. Graphs show the results (averages and standard deviations [SD]) of a representative experiment that was performed in quadruplicate. All experiments were repeated at least twice. For each compound, the calculated EC50, CC50, and SI values are given.
|
|
| S1457 |
Atazanavir SulfateAtazanavir Sulfate is a HIV protease inhibitor with Ki of 2.66 nM in a cell-free assay. |
Protease inhibitors induce macroautophagy. JEG3 were seeded on glass chamber slides (1 x 104 cell per chamber; 8-well μ slides; Ibidi, Martinsried, Germany), grown for 24 h under cell culture conditions, and treated for 24 h with 0-10 ug/ml of either lopinavir/ritonavir or atazanavir. Cells were then incubated for 30 min with the blue-green fluorescent autophagy marker monodansylcadaverine and viewed under a fluorescence microscope.
|
|
| S1620 |
Darunavir EthanolateDarunavir Ethanolate (DRV) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection. |
HIV PIs variably alter intracellular HIV epitope stability. (A) HLA-A02–restricted SL9 epitope (SLYNTVATL, aa 77–85 in HIV-1 Gag p17) was degraded in PBMC extracts pretreated with DMSO (control, circles), 5 µM of Nelfinavir (triangles) or 5 µM of Saquinavir (squares). Remaining peptide was quantified by RP-HPLC analysis after 0, 10, 30 and 60 minutes. 100% represents the amount of peptide at time 0 calculated as the surface under the peptide peak detected by RP-HPLC (815.986, 821.569, and 813.118 for DMSO, Saquinavir, and Nelfinavir, respectively). Times at which 50% of the SL9 peptide remained correspond to peptide half-lives (37 min, 52 min and 24 min for Control, Saquinavir and Nelfinavir respectively). (B–F) HLA-A02–SL9, HLA-B57-KF11, HLAB57-ISW9, HLA-B57-TW10 and HLA-A11-ATK9 epitopes (from B to F respectively) were degraded in PBMC extracts pretreated with DMSO, 2 µM or 5 µM PI (Saquinavir, Ritonavir, Nelfinavir, Atazanavir or Darunavir). The cytosolic half-lives in control condition were 33.87, 25.66, 14.83, 119.4 and 37.21 minutes for SL9, KF11, ISW9, TW10 and ATK9 respectively. Fold differences of each epitope half-life upon treatment compared to control are presented in each panel. All data represent the average of 4 different experiments using 4 different PBMC extracts. *P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA with Dunnett’s post-test. |
|
| S1639 |
AmprenavirAmprenavir is a potent PXR-selective agonist, and an HIV protease inhibitor, used to treat HIV. |
||
| S6625新 |
Temsavir (BMS-626529)Temsavir (BMS-626529) is a novel small-molecule HIV-1 attachment inhibitor active against both CCR5- and CXCR4-tropic viruses. |
||
| S6581新 |
Fosamprenavir calcium saltFosamprenavir is a pro-drug of the protease inhibitor and antiretroviral drug amprenavir. It is used for the treatment of HIV-1 infections. |
||
| S5250 |
DarunavirDarunavir is a nonpeptidic HIV protease inhibitor, used to treat HIV infection. |
||
| s9010 |
BevirimatBevirimat, the prototype Human Immunodeficiency Virus type 1 (HIV-1) maturation inhibitor, is highly potent in cell culture and efficacious in HIV-1 infected patients. |
||
| S2319 |
LimoninLimonin is a triterpenoid enriched in citrus fruits, which has antivirus and antitumor ability. |
||
| S4662 |
AtazanavirAtazanavir is an azapeptide and HIV-protease inhibitor that is used in the treatment of HIV infections and AIDS in combination with other anti-HIV agents. |
||
| S9567 |
Indinavir SulfateIndinavir sulfate is a specific and potent inhibitor of HIV-1 protease and is widely used in the treatment of AIDS. |
||
| S4282 |
Nelfinavir MesylateNelfinavir Mesylate is a potent HIV protease inhibitor with Ki of 2 nM. |
||
| S7381 |
Pepstatin APepstatin A is a potent aspartic protease inhibitor, and also inhibits HIV replication. |
||
| S5245 |
Raltegravir potassiumRaltegravir Potassium is the orally bioavailable potassium salt of raltegravir, the first approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor. |
